Associated Genetic Biomarkers
NCI Definition: A malignant mesenchymal fibroblastic neoplasm affecting the soft tissue and bone. 
Fibrosarcomas most frequently harbor alterations in TP53, CDKN2A, CDKN2B, EWSR1, and ATRX .
CDKN2A Loss, CDKN2B Loss, TP53 Mutation, TP53 Loss, and EWSR1 Fusion are the most common alterations in fibrosarcoma .
There are 4 clinical trials for fibrosarcoma, of which 4 are open and 0 are completed or closed. Of the trials that contain fibrosarcoma as an inclusion criterion, 2 are phase 1 (2 open), 1 is phase 1/phase 2 (1 open), and 1 is phase 2 (1 open).
Ganglioside and RB1 are the most frequent gene inclusion criteria for fibrosarcoma clinical trials .
Radiation therapy, surgery, and bo-112 are the most common interventions in fibrosarcoma clinical trials.
Significant Genes in Fibrosarcoma
2. The AACR Project GENIE Consortium. AACR Project GENIE: powering precision medicine through an international consortium. Cancer Discovery. 2017;7(8):818-831. Dataset Version 8. This dataset does not represent the totality of the genetic landscape; see paper for more information.